Peptides Similar to Bioglutide (NA-931)

Peptides Related to Bioglutide (NA-931)#

Bioglutide (NA-931) occupies a unique position in the anti-obesity therapeutic landscape as the only quadruple receptor agonist (IGF-1, GLP-1, GIP, glucagon) and the only multi-agonist designed for oral administration. It is compared below with the most clinically relevant agents, spanning approved therapies and investigational drugs.

All comparisons should be interpreted with caution given Bioglutide's early stage of development and the limitations of cross-trial comparisons.

Semaglutide (Ozempic / Wegovy / Rybelsus)#

Semaglutide is the most established GLP-1 receptor agonist, developed by Novo Nordisk with three FDA-approved formulations. It serves as the current standard of care for pharmacological weight management.

Mechanism comparison: Semaglutide activates only the GLP-1 receptor. Bioglutide activates four receptors (IGF-1, GLP-1, GIP, glucagon), providing broader metabolic pathway coverage. The additional receptors may contribute to enhanced energy expenditure (glucagon), improved body composition (IGF-1), and complementary insulin secretion (GIP).

Efficacy comparison: Semaglutide 2.4 mg achieved 14.9% weight loss at 68 weeks in STEP 1, while Bioglutide 150 mg achieved 13.8% at only 13 weeks. Direct comparison is not possible due to different trial durations and populations. If Bioglutide's weight loss trajectory continues beyond 13 weeks (which remains to be demonstrated), it could potentially match or exceed semaglutide's efficacy.

Route and convenience: Injectable semaglutide requires weekly subcutaneous injection. Oral semaglutide (Rybelsus) requires SNAC absorption enhancer, strict fasting, and limited water. Bioglutide is an oral capsule with no fasting or absorption enhancer requirements, representing a significant convenience advantage.

GI tolerability: Bioglutide's GI side effect profile (7.3% nausea, 6.3% diarrhea) is dramatically more favorable than semaglutide 2.4 mg (44% nausea, 30% diarrhea in STEP 1).

Cardiovascular evidence: Semaglutide has a decisive advantage with two positive CV outcomes trials (SUSTAIN-6 and SELECT), including a 20% MACE reduction in SELECT. Bioglutide has no CV outcomes data.

Tirzepatide (Mounjaro / Zepbound)#

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly, FDA-approved as Mounjaro (T2D, 2022) and Zepbound (weight management, 2023). A Phase 2 combination trial of Bioglutide with tirzepatide is underway (NCT06732245).

Mechanism comparison: Tirzepatide activates GIP and GLP-1 receptors. Bioglutide activates these same two receptors plus glucagon and IGF-1. The additional glucagon agonism provides enhanced energy expenditure, and IGF-1 agonism supports muscle preservation.

Efficacy comparison: Tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks in SURMOUNT-1, currently the highest weight loss of any approved anti-obesity medication. Bioglutide's 13.8% at 13 weeks cannot be directly compared, though the trajectory suggests potential for substantial further weight loss with longer treatment.

Combination potential: The ongoing Phase 2 combination trial (NCT06732245) is testing whether Bioglutide can enhance tirzepatide's efficacy while reducing its GI side effects and preserving muscle mass. Preclinical data showed synergistic effects.

Route: Tirzepatide is injectable only (weekly subcutaneous). Bioglutide is oral, potentially offering a complementary route in combination therapy.

Retatrutide (LY3437943)#

Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) developed by Eli Lilly, currently in Phase 3 development (TRIUMPH program). It represents the closest mechanistic comparator to Bioglutide, sharing three of four receptor targets.

Mechanism comparison: Retatrutide activates GIP, GLP-1, and glucagon receptors. Bioglutide adds IGF-1 receptor agonism. The key mechanistic difference is Bioglutide's IGF-1R activity for muscle preservation and its oral formulation.

Efficacy comparison: Retatrutide achieved approximately 24.2% weight loss at its highest dose (12 mg) at 48 weeks in Phase 2, the greatest weight reduction reported for any anti-obesity agent. Bioglutide's 13.8% at 13 weeks reflects a much shorter treatment period.

Development stage: Retatrutide is in Phase 3 (TRIUMPH program) with larger datasets. Bioglutide has completed Phase 2 with smaller trials. Retatrutide is backed by Eli Lilly's substantial resources.

Route: Retatrutide requires weekly subcutaneous injection. Bioglutide offers oral daily dosing.

Orforglipron (LY3502970)#

Orforglipron is an investigational oral small-molecule GLP-1 receptor agonist developed by Eli Lilly, currently in Phase 3 development (ATTAIN program). It is the most direct oral comparator to Bioglutide, though it targets only one receptor.

Mechanism comparison: Orforglipron is a selective GLP-1-only agonist. Bioglutide targets four receptors. Both are small molecules designed for oral daily dosing without absorption enhancers.

Efficacy comparison: In Phase 2, orforglipron achieved approximately 14.7% weight loss at the highest dose over 36 weeks. Bioglutide achieved 13.8% at 13 weeks. Both demonstrate that oral small molecules can achieve weight loss approaching injectable GLP-1 agonist levels.

GI tolerability: Orforglipron's Phase 2 data showed GI side effect rates similar to injectable GLP-1 agonists (nausea approximately 35-50% depending on dose). Bioglutide's 7.3% nausea rate, if confirmed, represents a significant tolerability advantage.

Development resources: Orforglipron is backed by Eli Lilly's Phase 3 program (ATTAIN) with thousands of participants. Bioglutide is from the smaller Biomed Industries with limited Phase 2 data.

Summary Comparison#

Key Differentiators#

Bioglutide's potential competitive advantages include:

1. Only quadruple agonist: No other agent targets all four receptors (IGF-1, GLP-1, GIP, glucagon)
2. Oral multi-agonist: The only multi-receptor agonist that is orally administered
3. Muscle preservation: The only anti-obesity agent to demonstrate muscle mass preservation during weight loss (attributed to IGF-1R agonism)
4. GI tolerability: Dramatically lower GI side effect rates than all current comparators
5. No fasting or absorption enhancer: Simpler administration than oral semaglutide

Bioglutide's key disadvantages include:

1. Limited data: Phase 2 only, small sample sizes, short treatment durations
2. No CV outcomes: No cardiovascular benefit demonstrated
3. Single sponsor: Biomed Industries is a small company compared to Novo Nordisk and Eli Lilly
4. No regulatory approval: Years away from potential FDA approval
5. Undisclosed structure: Molecular details, binding affinities, and complete PK data not publicly available

Related Reading#

• Bioglutide (NA-931) overview and research guide
• Bioglutide (NA-931) research evidence
• Bioglutide (NA-931) dosing protocols